Brind.

NRx Pharmaceuticals filed a petition with the FDA requesting the removal of the drug BZT.

1 report, 1 independent Updated Aug 14

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA

How it developed

Newest first. Tap a step to see who reported it.

Aug 7The FDA completed the first-cycle review of an Abbreviated New Drug Application (ANDA) involving NRx Pharmaceuticals and Teva.Sub-event
Aug 14NRx Pharmaceuticals petitioned the FDA to remove BZT from its portfolio.1 source
- NewMediaWire

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

FDA granted Fast Track designation to NRX-100 on September 4, 2025.Jun 7

Coverage

Newest first; wire copies grouped

Aug 14NewMediaWireNRx Pharmaceuticals (NASDAQ: NRXP) Petitions FDA to Ban Benzethonium Chloride From Ketamine Products LOS ANGELES, CA - August 13, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-